Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007;34(4):406-11.

In vivo evaluation of the HeartWare centrifugal ventricular assist device

Egemen Tuzun  1 , Katy Roberts, William E Cohn, Murat Sargin, Courtney J Gemmato, Branislav Radovancevic, O H Frazier
Affiliations

In vivo evaluation of the HeartWare centrifugal ventricular assist device

Egemen Tuzun et al. Tex Heart Inst J. 2007.

Abstract

In this study, long-term (90-day) hemocompatibility and end-organ effects of a centrifugal left ventricular assist device (the Heartware HVAD) were evaluated in 6 healthy sheep. The device was implanted into the left ventricular apex on beating hearts. The outflow graft of each device was anastomosed to the descending aorta. None of the sheep received anticoagulation or antiaggregation medication during the study. Hematologic and biochemical tests of liver and kidney function were performed pre-operatively (baseline) and throughout the study. Data associated with pump function were collected continuously until 90 +/- 1 days of support, at which time the sheep were humanely killed, and the end-organs were examined macroscopically and histopathologically. Hematologic and biochemical test results were within normal limits during the study period. There were no significant complications. Postmortem examination of the explanted organs revealed no evidence of ischemia or infarction, except in 2 sheep, in which small foci of infarction were detected in each of their left kidneys. There was no significant device failure. In all sheep, the pump's inflow and outflow conduits were free of thrombus. During the 90-day study, the HeartWare HVAD showed exceptional hemocompatibility and reliability, both of which are crucial to the clinical success of any implantable left ventricular assist device.

Keywords: Animals; assisted circulation/instrumentation; blood pump, centrifugal; equipment design; heart assist device, left ventricular; hemodynamic processes; heparin; sheep; thrombosis/prevention & control.

PubMed Disclaimer

Figures

None
Fig. 1 The HeartWare HVAD left ventricular assist device.
None
Fig. 2 The HeartWare HVAD pump flow rate as a function of speed and pump head pressure.
None
Fig. 3 The HeartWare HVAD titanium sewing ring.
None
Fig. 4 A, B) The HeartWare HVAD after 90 days of support: interior surfaces (left) and impeller surfaces (right) are clean.
See this image and copyright information in PMC

References

    1. Dembitsky WP, Tector AJ, Park S, Moskowitz AJ, Gelijns AC, Ronan NS, et al. Left ventricular assist device performance with long-term circulatory support: lessons from the REMATCH trial. Ann Thorac Surg 2004;78:2123–30. - PubMed
    1. Digiorgi PL, Reel MS, Thornton B, Burton E, Naka Y, Oz MC. Heart transplant and left ventricular assist device costs. J Heart Lung Transplant 2005;24:200–4. - PubMed
    1. Radovancevic B, Vrtovec B, Frazier OH. Left ventricular assist devices: an alternative to medical therapy for end-stage heart failure. Curr Opin Cardiol 2003;18:210–4. - PubMed
    1. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001; 345:1435–43. - PubMed
    1. Schmid C, Welp H, Klotz S, Baba HA, Wilhelm MJ, Scheld HH. Outcome of patients surviving to heart transplantation after being mechanically bridged for more than 100 days. J Heart Lung Transplant 2003;22:1054–8. - PubMed

Publication types

Substances